Nuvectis Pharma Inc. (NVCT)
| Bid | 9.23 |
| Market Cap | 218.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.97M |
| EPS (ttm) | -1.11 |
| PE Ratio (ttm) | -8.41 |
| Forward PE | -6.65 |
| Analyst | Buy |
| Ask | 9.97 |
| Volume | 84,511 |
| Avg. Volume (20D) | 119,286 |
| Open | 9.63 |
| Previous Close | 9.77 |
| Day's Range | 9.00 - 10.00 |
| 52-Week Range | 4.44 - 11.80 |
| Beta | 0.22 |
About NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey....
Analyst Forecast
According to 2 analyst ratings, the average rating for NVCT stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 60.60% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A ComebackThe company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 f...